Time-dependent exposure to inhaled ipratropium bromide was characterized as exposed vs unexposed within the past year, and recency of exposure and cumulative exposure within the past year.

Ipratropium bromide 0.5 mg/3 mL (0.017%), albuterol (as sulfate) 2.5 mg/3 mL (0.083%); soln for inh. Not for primary treatment of acute attack. Avoid excessive use. Discontinue if paradoxical ...

Ipratropium bromide 0.06% (42mcg/spray); aqueous soln. Ipratropium bromide, an anticholinergic (parasympatholytic) agent, has antisecretory properties which inhibit secretions from the serous and ...

Atrovent Inhalation Solution contains the active ingredient ipratropium bromide monohydrate. It belongs to a group of medicines called anticholinergic bronchodilators. Atrovent Inhalation Solution ...

In our study, we found an increased risk of CVE associated with the use of ipratropium bromide in patients with COPD. We found a significant effect of recency of exposure to ipratropium bromide on ...